Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
941-960 of 998 trials

Cystic Fibrosis: Nebulized Bacteriophage Treatment

We are studying a new nebulized treatment for adults with cystic fibrosis and chronic Pseudomonas lung infection. The goal is to see if it helps reduce the infection and improve lung function and quality of life.

Cystic Fibrosis≤3 monthsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Plaque Psoriasis: Oral Piclidenoson Study

We are testing an oral medication called piclidenoson for people with moderate-to-severe plaque psoriasis. The goal is to see if it can significantly improve skin symptoms compared to a placebo.

Plaque Psoriasis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyDermatology

Momelotinib for Anemia in Low-Risk Myelodysplastic Syndrome

We are studying whether momelotinib can improve red blood cell counts in patients with low-risk myelodysplastic syndrome. The trial also looks at the safety of this treatment.

Myelodysplastic Syndrome3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Metastatic Colorectal Cancer: Fruquintinib and Tislelizumab Study

We are studying a new treatment combining Fruquintinib and Tislelizumab for patients with metastatic colorectal cancer without active liver metastases. The goal is to evaluate its effectiveness and safety while also assessing quality of life.

Metastatic Colorectal Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Exenatide for Early Parkinson’s Disease Progression

We are studying whether Exenatide can slow down the progression of symptoms in people with early Parkinson’s disease. The trial will also assess the safety of this treatment over time.

Parkinson's Disease1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteEndocrinologyNeurology

Daratumumab for Myalgic Encephalomyelitis (ME/CFS)

We are studying whether the drug daratumumab can help reduce symptoms in people with moderate to severe ME/CFS. The trial will also assess its safety compared to a placebo.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteInfectious DiseasesNeurology

Acute Myeloid Leukemia: Bleximenib, Venetoclax, and Azacitidine Study

We are studying a combination of three medications for people with newly diagnosed acute myeloid leukemia who cannot receive intensive chemotherapy. The aim is to see if this combination works better than the standard treatment alone.

Acute Myeloid LeukemiaConfirmation phase (III)Investigational MedicinesPartially RemoteHematologyOncology

Refractory Epilepsy: YCJ-01 Cannabis Extract

We are studying a cannabis extract to see if it can help reduce seizures in patients with difficult-to-control epilepsy due to Tuberous Sclerosis Complex. The trial will also assess the safety of this treatment.

Tuberous Sclerosis ComplexRefractory Epilepsy in Tuberous Sclerosis Complex6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Intestinal Failure-Associated Liver Disease: NST-6179 Study

We are testing a new oral medication, NST-6179, for individuals with Intestinal Failure-Associated Liver Disease. The study aims to understand its safety and how it affects liver health.

Intestinal Failure-Associated Liver Disease3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteGastroenterologyHepatology

Ulcerative Colitis: Mirikizumab with Tirzepatide

We are studying whether combining mirikizumab with tirzepatide helps adults with moderately to severely active ulcerative colitis and obesity achieve better remission and weight loss than mirikizumab alone.

Obesity or OverweightUlcerative Colitis1-2 yearsConfirmation phase (III)16-20 visitsStandard MedicinesPartially RemoteEndocrinologyGastroenterology

Crohn’s Disease: Mirikizumab with Tirzepatide

We are studying whether a combination of mirikizumab and tirzepatide helps adults with moderately to severely active Crohn’s disease achieve better remission and weight loss than mirikizumab alone.

Crohn’s DiseaseObesity or Overweight1-2 yearsConfirmation phase (III)16-20 visitsStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyGastroenterology

TAILORED-PROM: Personalized Treatment for Preterm Premature Rupture of Membranes

We are studying if a customized antibiotic and steroid therapy can help prolong pregnancy and improve outcomes for mothers and newborns. This approach may reduce unnecessary antibiotic use compared to standard treatments.

Preterm Premature Rupture of Membranes>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteGynecology and ObstetricsInfectious Diseases

Irritable Bowel Syndrome: Saccharomyces boulardii CNCM I-745

We are studying whether a probiotic can help adults with non-constipated IBS feel better and improve their quality of life compared to a placebo.

Non-constipated Irritable Bowel Syndrome3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteGastroenterology

Breast Cancer: Typology-based Coaching with Ribociclib

We are studying whether personalized coaching and education can help patients with HR+ HER2- early breast cancer stay on their ribociclib treatment. This may improve their treatment experience and overall health outcomes.

Hormone Receptor Positive Breast CancerBreast Cancer>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInternal MedicineOncology

Chronic Cluster Headache: Low-Dose LSD Study

We are investigating whether a low dose of LSD can help reduce the frequency and severity of chronic cluster headaches. This study will assess both its effectiveness and safety compared to a placebo.

Chronic Cluster Headache≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Type 2 Diabetes: LY3457263 Treatment Study

We are testing a new medication, LY3457263, in people with type 2 diabetes who are not meeting their blood sugar goals on current treatments. The study will compare its effects to a placebo over 24 weeks.

Type 2 DiabetesEfficacy phase (II)11-15 visitsInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Heart Patients: Reduced Dose of Prasugrel

We are studying whether a lower dose of prasugrel is safe and effective for patients after heart procedures. The trial also looks at how well patients stick to this treatment compared to the usual approach.

Acute and Chronic Coronary SyndromeMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Influenza Vaccine Study: OVX836

We are testing the OVX836 influenza vaccine in healthy adults to see if it can prevent influenza compared to a placebo. This study will also look at the vaccine's safety and how well it triggers an immune response.

Influenza6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteInfectious Diseases

Diabetic Macular Edema: BI 1815368 Study

We are testing whether the oral medication BI 1815368 can improve vision in people with diabetic macular edema. The study will also look at the safety of this treatment over time.

Diabetic Macular Edema6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesPartially RemoteEndocrinologyOphthalmology

Head and Neck Cancer: NBTXR3 Treatment Study

We are studying a new treatment involving NBTXR3 with or without cetuximab for elderly patients with locally advanced head and neck cancer. The goal is to see if this approach improves survival compared to standard radiotherapy.

Head and Neck Cancer>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology